Rivaroxaban for the treatment of deep vein thrombosis. Drug costs were the product of drug price wholesale acquisition cost and treatment duration. Rivaroxaban for the treatment of deep vein thrombosis or. Original article lengthofstayandeconomicconsequenceswith. Published in 2012, einstein pe randomized 4,832 patients with acute pe to rivaroxaban or standard therapy with enoxaparin and a vka. Rivaroxaban or aspirin for extended treatment of venous. Rivaroxaban inhibits factorxa in the coagulation cascade. Einstein pe was an extension of the einstein program and was the first large, randomized study of rivaroxaban in the treatment of acute pe. Pdf rivaroxaban and the einstein clinical trial programme. Einstein healthcare network is a leading healthcare system with approximately 1,000 licensed beds and 8,500 employees serving the communities of philadelphia and montgomery county, pa. Rivaroxaban versus standard anticoagulation for acute. Rivaroxaban vs a vitamin k antagonist einsteindvt trial.
Longterm anticoagulation with rivaroxaban for preventing. On the basis of the results of this study, together with those of the apixaban for the extended treatment of deep vein thrombosis and pulmonary embolism trial, 5 apixaban provided a simple. Dvt prophylaxis clinical trials xarelto rivaroxaban. The use of rivaroxaban to treat patients with acute dvt was also studied einstein dvt trial. Patients were randomized to receive either oral rivaroxaban 10 mg once daily for 31 to 39 days with placebo injection, beginning 6 to 8 hours after wound closure, or subcutaneous. Safe and effective use of rivaroxaban for treatment of cancerassociated venous thromboembolic disease. Einstein dvt trial open label, randomized, noninferiority study of 3449 patients randomized to rivaroxaban 15 mg bid for 21 days followed by 20 mg daily for 3,6, or 12 months or subq enoxaparin followed by adjusted dose warfarin primary outcome. Efficacy and safety of rivaroxaban in the treatment of deep vein thrombosis thrombosis. Direct oral anticoagulants for the treatment of acute. Oral direct factor xa inhibitor rivaroxaban in patients with. Vte, following the einsteinpe and einsteindvt trials 812. Einstein clinical trial programme comprises three randomized phase iii studies of rivaroxaban for the treatment of vte and the longterm prevention of recurrent vte. Oct assist the research community with pre and post award management.
Reduceddosed rivaroxaban in the longterm prevention of. Randomized, phase 3, multicenter, openlabel, parallelgroup, activecontrolled, eventdriven, noninferiority studies einstein dvt and einstein pe with patients receiving xarelto at an initial dose of 15 mg twice daily with food for the first 3 weeks, followed by xarelto 20 mg once daily with food or. Recurrent vte in einstein dvt occurred in 36 rivaroxaban patients 2. Anticoagulants with nsaid or aspirin the jama network. This analysis evaluates the results of these studies in this subgroup of patients. Treatment with bodyweightadjusted rivaroxaban appears to be safe in children. Eligible patients were those who had an acute, symptomatic pe with or without symptomatic deepvein thrombosis dvt. Rivaroxaban is a new oral anticoagulant indicated for the treatment of venous thromboembolic events vte including deep vein thrombosis dvt and pulmonary embolism pe. Deep vein thrombosis dvt common signs and symptoms of pe. Among patients in the einstein choice trial who had completed a 6 to 12month course of anticoagulation for vte, extending anticoagulation with either prophylaxis 10 mg or treatment 20 mg doses of rivaroxaban for 1 year is superior to aspirin in reducing recurrent vte events. Between march 22, 2007, and march 12, 2011, 8281 patients 3449 in the einsteindvt trial and 4832 in the einsteinpe trial were enrolled at 314 sites in 38 countries. Approval of rivaroxaban for this indication was based on the results of the einstein dvt, einstein pe, and einstein ext phase iii clinical studies. Oral rivaroxaban versus enoxaparin with vitamin k antagonist. To compare the efficacy and safety of doacs with vkas for the treatment of vte separately in these subgroups of patients, we extracted data from four posthoc analyses of six randomised controlled trials recover i, recover ii, einsteindvt, einsteinpe, amplify, hokusaivte 912.
Updated january 2020 results from the einstein choice study, published in the new england journal of medicine in 2017, revealed important information about extended anticoagulation treatment in patients with venous thromboembolism vte. Oral direct factor xa inhibitor rivaroxaban in patients. Buller hr, lensing aw, prins mh, agnelli g, cohen a, gallus as, et al. The goal of the trial was to evaluate treatment of the oral direct factor xa inhibitor, rivaroxaban, compared with standard therapy among patients with symptomatic pulmonary embolism pe. In addition to data from einstein dvt, dr stuart connolly mcmaster university, hamilton, on will present data from the averroes trial, a study comparing apixaban bristolmyers squibbpfizer vs. Bodyweightadjusted rivaroxaban for children with venous. Einstein medical center philadelphia is the largest independent academic medical center in the philadelphia region annually training over 3,500 health professional students and 400 residents in more than 30. Length of hospital stay for all patients with vte in the einstein dvt and einstein pe trials n. Dec 21, 2018 buller hr, lensing aw, prins mh, agnelli g, cohen a, gallus as, et al. Shortness of breath sudden chest pain a feeling of apprehension sudden collapse coughing sweating bloody phlegm coughing up blood. Oral rivaroxaban for symptomatic venous thromboembolism. May 2012 national institute for health and clinical.
Rivaroxaban for the treatment of deep vein thrombosis or pulmonary embolism. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism ta261. The einstein pe study was a randomized, openlabel trial of the efficacy and safety of rivaroxaban as compared with standard therapy consisting of enoxaparin and a vitamin k antagonist in. A doseranging study evaluating oncedaily oral administration of the factor xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis.
Phase iii trials of new oral anticoagulants in the acute. A prespecified pooled analysis of the einstein dvt and einstein pe studies compared the efficacy and safety of rivaroxaban 15 mg twicedaily for 21 days, followed by 20 mg oncedaily with standardtherapy enoxaparin 1. This is a multicenter, randomized, openlabel, assessorblind, eventdriven, noninferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic dvt without symptomatic pe einstein dvt. Meier clinical event rates for recurrent pulmonary embolism, recurrent dvt, allcause mortality, and bleeding were obtained from einsteinchoice. Einstein choice trial north american thrombosis forum. This is a multicenter, randomized, openlabel, assessorblind, eventdriven, noninferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic dvt without symptomatic pe einsteindvt. Buller, academic medical center, amsterdam, the netherlands. The page includes a summary of phase iii clinical trials, an overview of indications under investigation by the different drugs and helpful services for patients and healthcare professionals. Background the einstein dvt study was a large, openlabel, randomised trial comparing rivaroxaban with the standard care enoxaparinvitamin k antagonist vka in patients with acute deep vein. Rivaroxaban and the einstein clinical trial programme. The authors 2018 treated with rivaroxaban or warfarin for. Final appraisal determination rivaroxaban for the treatment of deep vein thrombosis and prevention of deep vein thrombosis and pulmonary embolism issue date. Symptomatic recurrent venous thromboembolism, defined as fatalnonfatal pe or deep vein thrombosis. Pdf comparing oral rivaroxaban versus standard care in the.
Services include education and ongoing training, contract. The investigators participating in the einstein dvt and einstein extension studies are listed in. Dec 16, 20 the worldwide einstein dvt and einstein pe studies randomized 8282 patients with acute symptomatic deepvein thrombosis dvt andor pulmonary embolism pe and, for the first time in trials in this setting, included patients in china. In the einstein dvt and einstein pe trials, rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily thereafter was shown to be an effective and safe alternative to standard. Whats the best anticoagulation management for deep. This is a multicenter, randomized, openlabel, assessorblind, eventdriven, noninferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic pulmonary embolism pe with or without symptomatic deepvein thrombosis dvt einstein pe. The einstein programme has been designed to investigate the clinical utility of xarelto rivaroxaban in the treatment of deep vein thrombosis dvt and pulmonary embolism pe. Aug 03, 2017 updated january 2020 results from the einstein choice study, published in the new england journal of medicine in 2017, revealed important information about extended anticoagulation treatment in patients with venous thromboembolism vte. Oral rivaroxaban for symptomatic venous thromboembolism nejm.
Safe and effective use of rivaroxaban for treatment of. A new, potentially paradigm shifting trial, has been published on the treatment of acute deep vein thrombosis dvt. Pulmonary embolism included both fatal and nonfatal pulmonary embolism. The einstein programme has been designed to investigate the clinical utility of xarelto rivaroxaban in the treatment of deep vein thrombosis dvt and pulmonary embolism pe, and the prevention of recurrent dvt and pe. The treatment regimens that we confirmed in children with bodyweights of at least 20 kg and the revised treatment regimens that we predicted in those with bodyweights less than 20 kg will be evaluated in the einsteinjr phase 3 trial in children with acute venous thromboembolism. The einstendvt trial demonstrated that rivaroxaban is noninferior to standard therapy i. Pe was unprovoked in 65%, due to recent surgery or trauma in 17%, immobilization in 16%, estrogen therapy in 9%, and active cancer in 5%. Hospitalized dvt and pe patients in north american einstein trial. Originally published in 2012, the einstein pe trial was a randomized, openlabel, noninferiority trial involving 4,832 patients. Prespecified pooled analysis of the einsteindvt and einsteinpe randomized phase iii studies active treatment. Stockholm fixeddose rivaroxaban is at least as effective as current standard treatment for acute deep vein thrombosisand far simpler to use, based on the large phase iii einsteindvt trial presented in a hotline session at the congress. The einsten dvt trial demonstrated that rivaroxaban is noninferior to standard therapy i. This study was presented at the 25th congress of the international society on thrombosis and haemostasis, june 2025, 2015, toronto, on, canada. The einstein dvt and pe program evaluated the efficacy and safety of a 3month, 6month, or 12month course of oral rivaroxaban vs subcutaneous enoxaparin overlapping with and followed by international normalized ratioadjusted vitamin k antagonists vkas ie, warfarin or acenocoumarol in patients with acute symptomatic dvt, pe, or both.
Longterm anticoagulation with rivaroxaban for preventing recurrent vte a benefitrisk analysis of einsteinextension. Efficacy and safety of rivaroxaban for prevention of recurrent venous thromboembolism. This is a multicenter, randomized, openlabel, assessorblind, eventdriven, noninferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic pulmonary embolism pe with or without symptomatic deep. The efficacy of apixaban, a factor xa inhibitor like rivaroxaban, had not yet been demonstrated in a large trial. Between march 22, 2007, and march 12, 2011, 8281 patients 3449 in the einstein dvt trial and 4832 in the einstein pe trial were enrolled at 314 sites in 38 countries. Pdf comparing oral rivaroxaban versus standard care in. Similarly, secondary analysis 2 used data from akl et al. Outpatient dvt treatment protocol amazon web services. Table 3 comparison of design of vte studies that compared noacs with either lmwh and vkas or vkas einstein dvt 21 einsteinpe 22 recover i. The treatment regimens that we confirmed in children with bodyweights of at least 20 kg and the revised treatment regimens that we predicted in those with bodyweights less than 20 kg will be evaluated in the einstein jr phase 3 trial in children with acute venous thromboembolism. The results of the einsteindvt trial indicate that rivaroxaban is an effective and safe treatment for acute symptomatic dvt, said principal investigator, professor harry r.
Treatment of deep vein thrombosis dvt, pulmonary embolism pe, and reduction in the risk of recurrence of dvt and of pe. This website is a free of charge service from daiichi sankyo europe gmbh. Sep 28, 2014 between march 22, 2007, and march 12, 2011, 8281 patients 3449 in the einstein dvt trial and 4832 in the einstein pe trial were enrolled at 314 sites in 38 countries. Rivaroxaban for the treatment of deep vein thrombosis and. Rivaroxaban versus standard anticoagulation for acute venous. Sep 20, 20 a prespecified pooled analysis of the einstein dvt and einstein pe studies compared the efficacy and safety of rivaroxaban 15 mg twicedaily for 21 days, followed by 20 mg oncedaily with standardtherapy enoxaparin 1. Both einstein dvt and pe trials had a similar design. A prespecified pooled analysis of the einsteindvt and einsteinpe studies compared the efficacy and safety of rivaroxaban 15 mg twicedaily for 21 days, followed by 20 mg oncedaily with standardtherapy enoxaparin 1. Union and the united states for the treatment of acute dvt and pe and secondary prevention of dvt and pe. Rivaroxaban was dosed at 15 mg twice daily for the. Secondary analysis one used data from a trial by lee et al. Pe can be fatal, if you experience these signs or symptoms. The 20 apixaban for the initial management of pulmonary embolism and deepvein thrombosis as firstline therapy amplify trial randomized 5,395 adults with an acute proximal dvt 65% or pe 35% to apixaban or conventional therapy.
The primary efficacy endpoint was a composite of deep vein thrombosis or pulmonary embolism symptomatic, recurrent venous thromboembolism. Meier clinical event rates for recurrent pulmonary embolism, recurrent dvt, allcause mortality, and bleeding were obtained from einstein choice. In contrast to the trials examining dabigatran, apixaban and edoxaban,, which included combined dvt and pe patient populations, the einstein pe trial of rivaroxaban focused on a specific population of patients with pe with or without dvt. Patients were classified as patients with active cancer.
Einsteinpulmonary embolism pe study american college of. Office of clinical trials oct albert einstein college. Rivaroxaban for the treatment of symptomatic deepvein. Prespecified pooled analysis of the einstein dvt and einstein pe randomized phase iii studies active treatment. Originally published in 2012, the einsteinpe trial was a randomized, openlabel, noninferiority trial involving 4,832 patients. Clinical and applied practical management of rivaroxaban. The goal of the trial was to uncover the best form of extended vte treatment by comparing different doses of rivaroxaban with aspirin. Venous thromboembolism, which includes deepvein thrombosis and pulmonary embolism, is the third most common cause of vascular death after myocardial infarction and stroke. The office of clinical trials oct is the central administrative office for private funded research for montefiore medical center and albert einstein college of medicine. Prophylaxis of deep vein thrombosis following hip or knee replacement surgery. The worldwide einstein dvt and einstein pe studies randomized 8282 patients with acute symptomatic deepvein thrombosis dvt andor pulmonary embolism pe and, for the first time in trials in this setting, included patients in china. Healthcare cost impact of continued anticoagulation with.
930 312 821 1308 312 729 535 1367 571 807 786 1040 825 166 945 511 1255 967 907 1215 657 474 929 958 858 9 1097 1425